Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.310
+0.020 (0.61%)
At close: Aug 13, 2026, 4:00 PM EDT
3.300
-0.010 (-0.30%)
After-hours: Aug 13, 2026, 7:54 PM EDT
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenue of $7.67M in the quarter ending June 30, 2026, a decrease of -60.10%. This brings the company's revenue in the last twelve months to $54.86M, down -15.08% year-over-year. In the year 2025, Recursion Pharmaceuticals had annual revenue of $74.68M with 26.92% growth.
Revenue (ttm)
$54.86M
Revenue Growth
-15.08%
P/S Ratio
32.36
Revenue / Employee
$91,427
Employees
600
Market Cap
1.78B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 74.68M | 15.84M | 26.92% |
| Dec 31, 2024 | 58.84M | 14.26M | 32.00% |
| Dec 31, 2023 | 44.58M | 4.73M | 11.88% |
| Dec 31, 2022 | 39.84M | 29.67M | 291.46% |
| Dec 31, 2021 | 10.18M | 6.22M | 156.89% |
| Dec 31, 2020 | 3.96M | 1.64M | 70.85% |
| Dec 31, 2019 | 2.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.68B |
| Sarepta Therapeutics | 1.97B |
| Lakefront Biotherapeutics NV | 1.20B |
| Immunocore Holdings | 430.78M |
| Syndax Pharmaceuticals | 252.25M |
| Septerna | 98.88M |
| Ascentage Pharma Group International | 82.08M |
| Zymeworks | 37.13M |
RXRX News
- 2 days ago - Recursion Pharmaceuticals Transcript: Bank of America SMID Cap Virtual Conference - Transcripts
- 8 days ago - Recursion Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 8 days ago - Recursion Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 8 days ago - Recursion Pharmaceuticals Earnings release: Q2 2026 - Filings
- 8 days ago - Recursion Pharmaceuticals Slides: Q2 2026 - Filings
- 8 days ago - Recursion Pharmaceuticals reports Q2 EPS (25c), consensus (23c) - TheFly
- 8 days ago - Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program - GlobeNewsWire
- 9 days ago - Recursion to Participate in Upcoming Investor Conferences - GlobeNewsWire